Global bone cancer treatment market seen reaching $1.8 billion by 2031

Allied Market Research projects the global bone cancer treatment market will grow from $1.2 billion in 2021 to $1.8 billion by 2031, driven by steady demand across hospitals, pharmacies and newer drug categories. The report also flags osteosarcoma, immunotherapy and targeted therapy, North America and Asia-Pacific as the key segments to watch. Why it matters: - The report points to a growing market for bone cancer treatments, which can shape investment, product development and market-entry plans through 2031. - The forecast suggests steady demand even after the pandemic disruption that hit healthcare access. - Download the sample report for the full market breakdown. What happened: - Allied Market Research said the global bone cancer treatment market was valued at $1.2 billion in 2021. - The market is projected to reach $1.8 billion by 2031. - The report forecasts a 4.5% compound annual growth rate from 2022 to 2031. - Allied Market Research released the report on June 9, 2026, in Portland, Oregon. The details: - The study examines the market by type, end-use industry and region. - The report says the osteosarcoma segment held nearly three-fifths of total market revenue in 2021 and is expected to remain the largest segment by 2031. - The osteosarcoma segment is also projected to post the fastest CAGR in the type category at 4.7% during the forecast period. - By drug type, the immunotherapy and targeted therapy segment held more than two-thirds of total market revenue in 2021 and is expected to dominate by 2031. - The immunotherapy and targeted therapy segment is projected to grow at a 4.6% CAGR. - By distribution channel, hospital pharmacies accounted for more than half of total market revenue in 2021 and are expected to lead through 2031. - Online pharmacies are projected to record the fastest growth in the channel category, with a 5.3% CAGR. - By region, North America generated more than two-fifths of global market revenue in 2021 and is expected to keep the largest share by 2031. - Asia-Pacific is projected to grow fastest, with a 5.2% CAGR. - The report also covers Europe and LAMEA. - Key companies named in the report include Cancervax, Cellectar Biosciences, Pfizer, Advaxis, Isofol Medical, Gradalis, QSAM Biosciences, Takeda Pharmaceutical, Hikma Pharmaceutical and Zentalis Pharmaceuticals. - The report says these players have used partnerships, expansion, collaboration and joint ventures to strengthen their positions. Between the lines: - The market recovered after COVID-19-related facility closures and exposure concerns disrupted treatment access. - The segment mix suggests oncology drug innovation and hospital-based care still anchor the market, while online pharmacy growth points to a gradual shift in distribution. - The regional outlook implies the U.S. and broader North American market remain the commercial center, but Asia-Pacific is gaining momentum. What’s next: - Investors and market participants are expected to use the report to identify the highest-revenue and fastest-growing segments. - The forecast period through 2031 leaves room for new product launches, partnerships and geographic expansion among listed competitors. - More information is available through the purchase inquiry page .